Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines

Poolman, Jan; Borrow, Raymond

doi:10.1586/erv.11.8

Cited by 143 publications

(107 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As recognized for other PS, conjugation to an appropriate carrier protein overcomes the limits of PS vaccines, such as poor efficacy in children less than 2 y, lack of immunological memory with poor booster responses, and relatively short duration of protection (19)(20)(21). Meningococcal conjugate vaccines are also able to overcome the immune hyporesponsiveness that is induced by PS vaccines (22,23). Additionally, as documented for group C, meningococcal conjugate vaccines can reduce carriage of N. meningitidis in the nasopharynx, decreasing transmission (24), whereas PS vaccines have not been shown to provide substantial herd immunity (25).…”

Section: Significancementioning

confidence: 99%

Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X

Micoli

Romano

Tontini

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Neisseria meningitidis is a major cause of bacterial meningitis worldwide, especially in the African meningitis belt, and has a high associated mortality. The meningococcal serogroups A, W, and X have been responsible for epidemics and almost all cases of meningococcal meningitis in the meningitis belt over the past 12 y. Currently no vaccine is available against meningococcal X (MenX). Because the development of a new vaccine through to licensure takes many years, this leaves Africa vulnerable to new epidemics of MenX meningitis at a time when the epidemiology of meningococcal meningitis on the continent is changing rapidly, following the recent introduction of a glycoconjugate vaccine against serogroup A. Here, we report the development of candidate glycoconjugate vaccines against MenX and preclinical data from their use in animal studies. Following optimization of growth conditions of our seed MenX strain for polysaccharide (PS) production, a scalable purification process was developed yielding high amounts of pure MenX PS. Different glycoconjugates were synthesized by coupling MenX oligosaccharides of varying chain length to CRM 197 as carrier protein. Analytical methods were developed for in-process control and determination of purity and consistency of the vaccines. All conjugates induced high anti-MenX PS IgG titers in mice. Antibodies were strongly bactericidal against African MenX isolates. These findings support the further development of glycoconjugate vaccines against MenX and their assessment in clinical trials to produce a vaccine against the one cause of epidemic meningococcal meningitis that currently cannot be prevented by available vaccines.

show abstract

Section: Significancementioning

confidence: 99%

Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X

Micoli

Romano

Tontini

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Für wiederholte Impfungen mit Polysaccharid-Impfstoffen wurde bisher angenommen, dass eine abgeschwächte Impfantwort (sog. "hyporesponsiveness") entstehen kann [6,22]. Die Ergebnisse eines systematischen Reviews ergaben jedoch, dass eine wiederholte Impfung mit PPSV23 nicht mit einer dauerhaften Hyporesponsivität verbunden war [23].…”

Section: Bekanntmachungen -Amtliche Mitteilungenunclassified

Impfen bei Immundefizienz

Niehues

Bogdan

Hecht

et al. 2017

Bundesgesundheitsbl

View full text Add to dashboard Cite

“…4 Although no routine Canadian recommendations for offering this vaccine to asplenic adults are available, some experts recommend that clinicians consider using a protein-conjugated pneumococcal vaccine as the initial dose, followed by the polysaccharide vaccine, as this may theoretically improve antibody response and immunologic memory. 2,5 In June 2012, the United States Advisory Committee on Immunization Practices voted to recommend Prevnar 13 for use in people aged 19 years or older with functional or anatomic asplenia. 6 Physicians should also ensure that adult asplenic persons are offered all routine adult vaccines.…”

Section: Terry Wuerz MD Matt Seftel Md Mphmentioning

confidence: 99%